about
Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysisHow do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experimentMethotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysisSelecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task ForceCost-effectiveness of nurse practitioners in primary and specialised ambulatory care: systematic reviewBest practices for cardiovascular disease prevention in rheumatoid arthritis: a systematic review of guideline recommendations and quality indicatorsApplying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: report of the ISPOR simulation modeling emerging good practices task forceUsing and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.Handling uncertainty in economic evaluations of patient level data: a review of the use of Bayesian methods to inform health technology assessments.Hip resurfacing versus total hip arthroplasty: a systematic review comparing standardized outcomesAccess to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatmentDiscordant indigenous and provider frames explain challenges in improving access to arthritis care: a qualitative study using constructivist grounded theoryAddressing the challenges of the clinical application of pharmacogenetic testingLooking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses.An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening.Transforming Healthcare Delivery: Integrating Dynamic Simulation Modelling and Big Data in Health Economics and Outcomes Research.Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada.Essay for the CIHR/CMAJ award: improving access to hip and knee replacement and its quality by adopting a new model of care in Alberta.You'll know when you're ready: a qualitative study exploring how patients decide when the time is right for joint replacement surgery.Do economic evaluations of targeted therapy provide support for decision makers?Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology.Capacity building for assessing new technologies: approaches to examining personalized medicine in practiceThe value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatmentOptimizing the interprofessional workforce for centralized intake of patients with osteoarthritis and rheumatoid disease: case study.Measuring the value of total hip and knee arthroplasty: considering costs over the continuum of careValue of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online SampleKaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysisDevelopment of key performance indicators to evaluate centralized intake for patients with osteoarthritis and rheumatoid arthritis.Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping reviewDevelopment of Cardiovascular Quality Indicators for Rheumatoid Arthritis: Results from an International Expert Panel Using a Novel Online Process.Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada.Economic evaluation of targeted cancer interventions: critical review and recommendations.The use of a policy dialogue to facilitate evidence-informed policy development for improved access to care: the case of the Winnipeg Central Intake Service (WCIS).Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.What are people willing to pay for whole-genome sequencing information, and who decides what they receive?Does bearing size influence metal ion levels in large-head metal-on-metal total hip arthroplasty? A comparison of three total hip systems.How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice surveyPatients' perceptions of gene expression profiling in breast cancer treatment decisions.Societal values in the allocation of healthcare resources: is it all about the health gain?
P50
Q24202055-9BB7B6E7-256F-403C-87C5-D0930AC7BED1Q24658523-2B537AAB-C2D0-4A75-9A72-AF46FAD13D6AQ26751187-EBC6C6DA-A51D-45A7-8E52-EFD01EAA1D40Q26822464-E3EDECBC-620F-454A-A35C-2C1DB6003FC1Q26827730-5C71ED54-69BB-42FD-BB5F-C3A2F110B49FQ26864064-2B20E23D-63A8-4C75-A3F4-DB3A5C87361EQ28084009-20C126A7-FB2E-4BBE-896E-0B2A5EEE2105Q31037061-1D9A69E3-683A-46E3-81EA-1F987BA807DCQ31130672-9886F646-3F85-4C79-AFA7-B2B8ED672051Q33511681-85265038-4CF4-46AD-BFE6-9B57E9A63F87Q33722159-A7CDD275-5CBC-4EC4-8946-78F939D887F9Q33763903-243039C9-7CB2-40D4-B833-0CD3680A79EEQ33818520-9FEF0F0E-1DAE-492F-B2F3-50992F40F1C1Q34022094-F84ABA45-EE27-4412-9856-7922A3C2D01AQ34022527-359C00FC-51FE-4D1C-8292-42D2CBA9DFE3Q34164094-67586091-2C8D-4792-BA88-1CEF10D2E5DBQ34499256-68C07C35-4ADA-4769-BACA-A7BBE9239C0EQ34509277-8C571A2B-2D74-4B97-8A4A-7D34BCCC5BFBQ34765275-00426BED-1B1C-468E-83BF-E51A8FCE2936Q34811703-1900E0FD-37AC-4F98-95FC-B19435085F6DQ34974213-A815D9C6-8473-4DEE-804C-BCAB5C1AB20DQ35002357-F8784AD6-506D-4C9D-8883-087848FC9239Q35167656-BC477556-EEBE-4B22-8704-AAA1F2A758A2Q35345599-CD08D207-4149-4868-BA07-8BE7FC818E79Q35663303-5BF765C3-B662-4B33-ADC7-C1FFA0B2BC9DQ35802890-F8987C9A-E0B9-499A-9546-140518FD1973Q35850612-6A99870A-27E6-4C09-9A39-1FE93000CCD0Q36100899-CF4E0F61-90F0-4CD9-A542-199A38AF86D2Q36278380-3C4FE2B4-29B2-4BEB-B49C-7DE62D8B9B5AQ36304418-C36C4EDF-85C6-4F73-9CCD-58D4441D638CQ36593810-AEE7BCAE-18A2-4225-A09E-58421228C3E6Q37167573-8A7B266F-F351-4838-A0DE-A375357910D5Q37173971-9BB5089C-916C-4339-A51A-C0F687679170Q37350402-475B7B4D-8A96-4578-A6F7-25667E8C6B49Q37438148-2D109E5C-04E1-4A85-AD74-89F180310318Q37463453-B48463CE-FE13-469B-BDAB-A6505F3FE210Q37562859-E2A56637-8FFA-4B53-B59E-F0AA7715D1B3Q37661469-85FF6CA5-F184-49AD-9743-3E28B49115B7Q37719617-00977980-3BD2-4694-A383-71FDE87B042AQ37911500-D6113D25-8FFE-4ADE-BF77-95E6596BA0EE
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Deborah Marshall
@ast
Deborah Marshall
@en
Deborah Marshall
@es
Deborah Marshall
@nl
Deborah Marshall
@sl
type
label
Deborah Marshall
@ast
Deborah Marshall
@en
Deborah Marshall
@es
Deborah Marshall
@nl
Deborah Marshall
@sl
prefLabel
Deborah Marshall
@ast
Deborah Marshall
@en
Deborah Marshall
@es
Deborah Marshall
@nl
Deborah Marshall
@sl
P214
P1053
J-7248-2015
P106
P1153
7402186337
P21
P214
P2456
P31
P3829
P496
0000-0002-8467-8008
P734
P735
P7859
viaf-271363319